SANA (Sana Biotechnology) Total Payout Ratio : 0.61 (As of Mar. 04, 2025)

View and export this data going back to 2021. Start your Free Trial

What is Sana Biotechnology Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Sana Biotechnology's current Total Payout Ratio is 0.61.

Sana Biotechnology Total Payout Ratio Historical Data

The historical data trend for Sana Biotechnology's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sana Biotechnology Total Payout Ratio Chart

Sana Biotechnology Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Payout Ratio

Get a 7-Day Free Trial

1.78

0.02

0.11

Sana Biotechnology Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Payout Ratio	Get a 7-Day Free Trial															0.01	0.05	1.69	-0.01	-

Competitive Comparison of Sana Biotechnology's Total Payout Ratio

For the Biotechnology subindustry, Sana Biotechnology's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sana Biotechnology's Total Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sana Biotechnology's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Sana Biotechnology's Total Payout Ratio falls into.

Sana Biotechnology Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Sana Biotechnology's Total Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	31.646	+	0)	/	-283.255
	=	0.11

Sana Biotechnology's Total Payout Ratio for the quarter that ended in Jun. 2024 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	-0.439	+	0)	/	-50.291
	=	-0.01

Sana Biotechnology Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of Sana Biotechnology's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Sana Biotechnology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sana Biotechnology Inc (NAS:SANA) » Definitions » Total Payout Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

188 East Blaine Street, Suite 400, Seattle, WA, USA, 98102

Website

https://www.sana.com

Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 among others.

Executives

Richard Mulligan	director, officer: Head of SanaX	C/O ICAHN CAPITAL LP, 767 FIFTH AVENUE, SUITE 4700, NEW YORK NY 10153
Patrick Y Yang	director	C/O GENENTECH INC, 1 DNA WAY,MS 49,ATTN:K.STRAND OR J.BERRY, SOUTH SAN FRANCISCO CA 94080-4990
Keith Crandell	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Robert Nelsen	director	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Fund X Overage, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Christian Hordo	officer: SVP, Chief Business Officer	C/O SANA BIOTECHNOLOGY, INC., 188 EAST BLAINE STREET, SUITE 400, SEATTLE WA 98102
Flagship Ventures Fund V, L.p.	10 percent owner	ONE MEMORIAL DRIVE, 7TH FLOOR, CAMBRIDGE MA 02142
Douglas E Williams	officer: EVP & President, R&D	C/O AMGEN INC, ONE AMGEN CENTER DR, THOUSAND OAKS CA 91320-1799
Bernard J Cassidy	officer: EVP & General Counsel	C/O TUMBLEWEED COMMUNICATIONS CORP, 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
James J. Macdonald	officer: See Remarks	C/O SANA BIOTECHNOLOGY, INC., 188 EAST BLAINE STREET, SUITE 400, SEATTLE WA 98102
Sunil Agarwal	officer: See Remarks	60 LEVERONI COURT, NOVATO CA 94949
Flagship Venturelabs V Llc	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Flagship V Venturelabs Rx Fund, L.p.	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Arch Venture Fund Ix, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Fund Ix Overage, L.p.	10 percent owner	8725 W. HIGGINS ROAD, SUITE 290, CHICAGO IL 60631